All Albumin Biomanufacturing Biosimilar policy VHH The future of cell and gene therapy depends on recombinant albumin Navigating the pitfalls of indication switching Can optimised manufacturing tip the scale for protein products? Biosimilar policymaking is caught in a tender trap ⟨ Page 1 Page 2 Page 3
